NCT00044759View on ClinicalTrials.gov

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

PHASE3CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Study Completion Date

January 31, 2003

Conditions

Hematologic Neoplasms

Interventions

DRUG

Piperacillin/Tazobactam (Tazocin)

Trial Locations (36)

7601

Hackensack

10021

New York

10466

The Bronx

10595

Valhalla

14263

Buffalo

14621

Rochester

18840

Sayre

19013

Upland

19104

Philadelphia

19107

Philadelphia

19611

West Reading

29203

Columbia

31792

Thomasville

32610

Gainesville

33169

North Miami

33705

St. Petersburg

34474

Ocala

40202

Louisville

52242

Iowa City

53226

Milwaukee

60611

Chicago

60637

Chicago

72205

Little Rock

74136

Tulsa

77030

Houston

80205

Denver

90089

Los Angeles

08103

Camden

14642-8668

Rochester

02908

Providence

26506-9162

Morgantown

Unknown

Hamilton

H1T 2M4

Montreal

K1H 8L6

Ottawa

S7N 0W8

Saskatoon

R3A 1r9

Winnepeg

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00044759 - Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma | Biotech Hunter | Biotech Hunter